FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Gilenya News Channel
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week
July 2013   
September 2013   
October 2013   
June 2014   
July 2014   
January 2015   
February 2015   
March 2015   
April 2015   
May 2015   
July 2015   
March 2016   
April 2016   
May 2016   
June 2016   

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

Oral Gilenya (fingolimod) reduces glutamate-mediated intracortical excitability in relapsing–remitting multiple sclerosis: STUDY
































Abstract

Objective
Fingolimod is an effective disease modifying therapy for multiple sclerosis (MS). Beyond its main action on peripheral lymphocytes, several noteworthy side effects have been demonstrated in vitro, among which modulation of neural excitability. Our aim was to explore cortical excitability in vivo in patients treated with fingolimod 0.5 mg/day.

Methods
Paired-pulse TMS was applied on the left primary motor cortex in 13 patients affected by relapsing–remitting MS, the day before the first dose of fingolimod (T0) and 60 days later (T1). Resting motor threshold, baseline motor evoked potentials, short interval intracortical inhibition (at 1, 3, 5 ms) and intracortical facilitation (at 7, 9, 11 and 13 ms) were estimated at T0 and T1.

Results
Intracortical facilitation was reduced at T1, without any changes in short interval intracortical inhibition.

Conclusions
Fingolimod selectively reduced intracortical facilitation, which is mainly mediated by glutamate.

Story Source: The above story is based on materials provided by CLINICALNEUROPHYSIOLOGY
Note: Materials may be edited for content and length

Labels: